Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
NCT05339217
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
Telitacicept
DRUG:
Interleukin-2
Sponsor
Liu Tian